Related Experiment Video

Updated: Dec 18, 2025

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

1.3K

Hepatitis C and Treatment in Patients with Chronic Kidney Disease

Abhijay Jalota1, Brian K Lindner1, Beje Thomas2

  • 1MedStar Georgetown University Hospital, 3800 Reservoir Rd NW, Washington, DC 20007, United States.

Disease-A-Month : DM
|June 20, 2020
PubMed

Insights

Hepatitis C virus (HCV) treatment for chronic kidney disease (CKD) patients has improved significantly with direct-acting antiviral agents (DAAs). DAAs offer high sustained viral response rates and minimal side effects, even for those with advanced CKD or post-transplant.

Area of Science:

  • Nephrology
  • Hepatology
  • Virology

Background:

  • Hepatitis C virus (HCV) infection significantly increases mortality and morbidity in patients with chronic kidney disease (CKD).
  • Early detection and treatment of HCV in CKD patients are crucial to prevent kidney function decline.
  • Previous interferon and ribavirin treatments had limited efficacy, frequent adverse events, and were contraindicated in advanced CKD, dialysis, and transplant patients.

Purpose of the Study:

  • To highlight the advancements in HCV treatment for CKD patients.
  • To emphasize the benefits of direct-acting antiviral agents (DAAs) in this population.
  • To discuss the impact of DAAs on kidney transplantation.

Main Methods:

  • Review of current literature on HCV treatment in CKD.
  • Analysis of efficacy and safety data for direct-acting antiviral agents (DAAs).
  • Evaluation of the role of DAAs in kidney transplant protocols.

Main Results:

  • Direct-acting antiviral agents (DAAs) achieve sustained viral response (SVR) rates of 90-100% in CKD patients with minimal side effects.
  • DAAs are now a viable treatment option for patients with advanced CKD, on dialysis, or who have received a kidney transplant.
  • DAAs facilitate the use of HCV-positive donor kidneys for HCV-negative recipients, increasing transplant rates.

Conclusions:

  • Direct-acting antiviral agents (DAAs) represent a major breakthrough in managing Hepatitis C virus (HCV) in chronic kidney disease (CKD) patients.
  • DAA therapy improves outcomes and expands treatment eligibility for CKD patients, including those with end-stage renal disease and transplant recipients.
  • Careful consideration of patient-specific factors is necessary when selecting the optimal DAA regimen.

Keywords:
CKD-chronic kidney diseaseDAA- Direct acting anti-viral agentsHCV-hepatitis C virusINF- interferonSVR-sustained viral response

More Related Videos

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice09:03

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice

Published on: February 3, 2012

19.7K
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.3K

Related Concept Videos

Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
259
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
219
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
145
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
446
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
444
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy01:26

Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in...
102